Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Durelli

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 1, 1995
Interferon alpha treatment of relapsing-remitting multiple sclerosis: long-term study of the correlations between clinical and magnetic resonance imaging results and effects on the immune functionL Durelli, M R Bongioanni, R Cavallo, et al.
Neurology|July 1, 1996
Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: disease activity resumes after stopping treatmentL Durelli, M R Bongioanni, B Ferrero, et al.
Journal of the Neurological Sciences|November 24, 2001
Thyroid function and anti-thyroid antibodies in MS patients screened for interferon treatment. A multicenter studyL Durelli, A Oggero, E Verdun, et al.
Neurology|March 1, 1994
Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosisL Durelli, M R Bongioanni, R Cavallo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 1, 1996
Long term recombinant interferon alpha treatment in MS with special emphasis to side effectsL Durelli, M R Bongioanni, B Ferrero, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 30, 2000
A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbationsD M Miller, B Weinstock-Guttman, F Béthoux, et al.
Neurology|October 1, 1976
Further observations on carbamazepine plasma levels in epileptic patients. Relationships with therapeutic and side effectsF Monaco, A Riccio, P Benna, et al.
Expert Opinion on Biological Therapy|March 13, 2009
Neutralizing antibodies in multiple sclerosis patients treated with 375 micrograms interferon-beta-1bL Durelli, P Barbero, A Cucci, et al.
Lancet (London, England)|May 30, 2001
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised studyG Comi, M Filippi, F Barkhof, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 8, 2007
MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosisL Durelli, P Barbero, M Bergui, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 1, 1995
Interferon alpha treatment of relapsing-remitting multiple sclerosis: long-term study of the correlations between clinical and magnetic resonance imaging results and effects on the immune functionL Durelli, M R Bongioanni, R Cavallo, et al.
Neurology|July 1, 1996
Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: disease activity resumes after stopping treatmentL Durelli, M R Bongioanni, B Ferrero, et al.
Journal of the Neurological Sciences|November 24, 2001
Thyroid function and anti-thyroid antibodies in MS patients screened for interferon treatment. A multicenter studyL Durelli, A Oggero, E Verdun, et al.
Neurology|March 1, 1994
Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosisL Durelli, M R Bongioanni, R Cavallo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 1, 1996
Long term recombinant interferon alpha treatment in MS with special emphasis to side effectsL Durelli, M R Bongioanni, B Ferrero, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 30, 2000
A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbationsD M Miller, B Weinstock-Guttman, F Béthoux, et al.
Neurology|October 1, 1976
Further observations on carbamazepine plasma levels in epileptic patients. Relationships with therapeutic and side effectsF Monaco, A Riccio, P Benna, et al.
Expert Opinion on Biological Therapy|March 13, 2009
Neutralizing antibodies in multiple sclerosis patients treated with 375 micrograms interferon-beta-1bL Durelli, P Barbero, A Cucci, et al.
Lancet (London, England)|May 30, 2001
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised studyG Comi, M Filippi, F Barkhof, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 8, 2007
MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosisL Durelli, P Barbero, M Bergui, et al.
Pageof 10